Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis With Liver Fibrosis as Predictors of New-Onset Diabetes Mellitus in People Living With Human Immunodeficiency Virus: A Longitudinal Cohort Study

Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease

(2023) Giovanni Targher et al.   Lancet Gastroenterology & Hepatology

PNPLA3 Genotype and Diabetes Identify Patients With Nonalcoholic Fatty Liver Disease at High Risk of Incident Cirrhosis

(2023) Vincent L. Chen et al.   GASTROENTEROLOGY

Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial

(2023) Rohit Loomba et al.   Lancet Gastroenterology & Hepatology

HIV is associated with elevated FibroScan-AST (FAST) score

(2022) Jennifer C. Price et al.   CLINICAL INFECTIOUS DISEASES

Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

(2022) Amalia Gastaldelli et al.   Lancet Diabetes & Endocrinology

Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain

(2022) Kai Juhani Kauppinen et al.   AIDS

Factors associated with liver steatosis in people living with HIV on contemporary antiretroviral therapy

(2022) Carlotta Riebensahm et al.   Open Forum Infectious Diseases

The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis

(2022) Kiarash Riazi et al.   Lancet Gastroenterology & Hepatology

Weight Change Following Antiretroviral Therapy Switch in People with Viral Suppression: Pooled Data from Randomized Clinical Trials

(2021) Kristine M Erlandson et al.   CLINICAL INFECTIOUS DISEASES

The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk

(2021) Cyrielle Caussy et al.   Current Diabetes Reports

Weight gain before and after switch from TDF to TAF in a U.S. cohort study

(2021) Patrick WG Mallon et al.   Journal of the International AIDS Society

Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial

(2021) Onyema Ogbuagu et al.   Lancet HIV

Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease

(2021) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study

(2020) Philip N Newsome et al.   Lancet Gastroenterology & Hepatology

Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping

(2020) Zhipeng Liu et al.   JOURNAL OF HEPATOLOGY

HIV and antiretroviral therapy-related fat alterations

(2020) John R. Koethe et al.   Nature Reviews Disease Primers

Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals

(2020) Alessandro Mantovani et al.   GUT

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

(2020) Philip N. Newsome et al.   NEW ENGLAND JOURNAL OF MEDICINE

Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis

(2018) Cyrielle Caussy et al.   HEPATOLOGY

96 weeks treatment of tenofovir alafenamide vs . tenofovir disoproxil fumarate for hepatitis B virus infection

(2018) Kosh Agarwal et al.   JOURNAL OF HEPATOLOGY

Factors Associated With Insulin Resistance in Adults With HIV Receiving Contemporary Antiretroviral Therapy: a Brief Update

(2018) Todd Hulgan   Current HIV/AIDS Reports

Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV mono-infection under long-term combined antiretroviral therapy

(2018) Hugo Perazzo et al.   Journal of the International AIDS Society

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis

(2017) Thomas Karlas et al.   JOURNAL OF HEPATOLOGY

Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments

(2017) Hironori Kitade et al.   Nutrients

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

Implications of Efficient Hepatic Delivery by Tenofovir Alafenamide (GS-7340) for Hepatitis B Virus Therapy

(2015) Eisuke Murakami et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study

(2014) I. Vodkin et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Controlled attenuation parameter (CAP) for the diagnosis of steatosis: A prospective study of 5323 examinations

(2014) Victor de Lédinghen et al.   JOURNAL OF HEPATOLOGY

Meta-analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis

(2013) Simona Bota et al.   LIVER INTERNATIONAL

Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis

(2010) Herbert Tilg et al.   HEPATOLOGY